Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.

Journal of medicinal chemistry - 22 Feb 2024

Lv Yan, Yang Zixuan, Chen Yiming, Ma Xuepei, Guo Mengqi, Zhang Chengwei, Jiang Xiaolin, Wang Chengli, Li Zhuoyue, Tai Zhengfu, Wang Xiao, Zhang Siqi, Ma Shumin, Qin Chong

Abstract excerpt

AMG510, as the first approved inhibitor for KRASG12C mutation, has shown promising efficacy in nonsmall-cell lung cancer and colorectal cancer harboring KRASG12C mutation. However, the moderate response rate and the rapid emergence of acquired resistance limit the therapeutic potential of AMG510, highlighting the need for the development of combination strategies. Here, we observed the suppression of RAS-MAPK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 38316747
DOI: 10.1021/acs.jmedchem.3c01598

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.PMID 38316747Read ↗

Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations.Semantic proximity Read ↗

SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Semantic proximity Read ↗

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance.Semantic proximity Read ↗

Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.Semantic proximity Read ↗

Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.Semantic proximity Read ↗

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D.Semantic proximity Read ↗

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.Semantic proximity Read ↗

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity Read ↗

Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer.Semantic proximity Read ↗

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia.Semantic proximity Read ↗

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC.Semantic proximity Read ↗

Targeting cancer with small molecule pan-KRAS degradersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.